Categories: CauseTechnology
Transformative RNA-Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Genetic Diseases Our innovative RNA-based therapies, based on Antisense Oligonucleotides (ASOs) restore protein functionality, addressing untreatable genetic pulmonary illnesses. TECHNOLOGY PIPELINE Transformative RNA-Based Treatments SpliSense is a company developing transformative RNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses. Our treatment […]
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.06.2026 | - | $13M | - |
| 14.05.2021 | Series B | $28.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 16.06.2026 | SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis | Cystic Fibrosis Foundation funding follows positive SPL84 Phase 2a clinical results demonstrating clinical proof-of-concept for an inhaled antisense oligonucleotide therapy in a lung disease. Funding supports the ongoing global Phase 2b stu... |
| 16.06.2026 | SpliSense Raises Up to $13M in Funding | SpliSense, a Jerusalem, Israel-based clinical-stage biotechnology company, raised up to $13M in funding.
The round was led by Cystic Fibrosis Foundation.
The company intends to use the funds to support the continued clinical development of ... |
| 14.09.2025 | SpliSense Reports Positive Results from Phase 2 Study of SPL84 in Cystic Fibrosis | Results mark first evidence of potential clinical benefit of antisense oligonucleotide therapy in a pulmonary disease Encouraging safety profile with no identified safety signals to date Improvement in lung function observed in up to 70% of... |
| 03.04.2024 | SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis | – Funding secured from CF Foundation and current investors for SPL84 Phase 2 study – – Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ — SpliSense... |
| 03.04.2024 | CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations | The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Fou... |
| 03.06.2023 | Глубокий вдох для лечения редкого заболевания легких | 3 июня 2023 г. Прорывная терапия редкой и потенциально смертельной формы заболевания легких заключается в лечении пациентов в домашних условиях с помощью короткого еженедельного или двухнедельного сеанса с небулайзером — аппаратом, который ... |
| 13.05.2021 | SpliSense Secures $28.5 Million in Series B Financing | Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation participated in the round. |
| 13.05.2021 | SpliSense : Secures $28.5 Million in Series B Financing | JERUSALEM, May 13, 2021 /PRNewswire/ -- SpliSense, a biopharmaceutical company developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, today announced that it has closed a $28.5 milli... |
| - | Splisense | - |
Reviews 0
